FDA Sends Complete Letter Response for IV Tramadol

October 12, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

FDA predicts opioid stacking may occur because of the acute pain treatment.

The US Food and Drug Administration (FDA) is requesting more information before approving intravenous tramadol for patients in acute pain who require an opioid.

Avenue Therapeutics announced the Complete Response Letter (CRL) for the New Drug Application (NDA) on Oct. 12.

The NDA included data from phase 3 clinical trials showing statistically significant outcomes for all primary endpoints, as well as several of the secondary endpoints.

However, in the CRL, the FDA said the treatment is not safe for the patient population it is intended to treat. The FDA said if a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic is needed. This would likely mean the patient would need another opioid, resulting in opioid “stacking.”

Ultimately, this scenario would increase the likelihood of opioid-related adverse effects.

The FDA also did not identify a safety signal in the clinical development program for the treatment and is requiring an adequate terminal sterilization validation prior to approval of the NDA. Avenue state the terminal sterilization validation is planned for completion by the end of the year.

“We believe that our extensive clinical database strongly supports the value of treatment with IV tramadol as an effective alternative to intravenous Schedule II conventional opioids,” Lucy Lu, MD, President and Chief Executive Officer of Avenue Therapeutics, said in a statement. “We firmly stand behind the safety data in our NDA and the ultimate approvability of IV tramadol. We will request a meeting with the FDA as soon as possible and are committed to working closely with the agency to resolve these issues in order to bring this important medicine to patients and clinicians in the U.S.”